XBI — State Street SPDR S&P Biotech ETF
Healthcare Ranked #60 of 458 tracked ETFs · Issued by State Street Investment Management
XBI Price Performance — Growth of $10,000
Value of a $10,000 investment in XBI over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
XBI Drawdown
The "underwater" chart: XBI's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in XBI?
See what a lump sum in XBI would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The State Street SPDR S&P Biotech ETF (XBI) operates within the Healthcare category, which currently contains 11 ETFs tracked by ETFValuer. Managed by State Street Investment Management, the fund has accumulated assets under management of $10.7 billion and trades at a price of $149.78. It holds an overall rank of #60 out of 458 tracked ETFs across all categories, earning an ETFValuer grade of B with a score of 73.6 out of 100. The fund charges an expense ratio of 0.35% and offers a dividend yield of 0.36%. The substantial asset size and mid-tier ranking suggest significant investor adoption relative to the broader universe of 458 funds. This positioning indicates the fund is a established vehicle within its specific sector despite not being the top-ranked option in its category.
Recent short-term performance shows declines, with the fund down 0.54% over one day, 3.06% over one week, and 3.60% over one month. However, the trend reverses significantly over longer horizons, posting a 12.69% gain over three months and 17.26% over six months. Year-to-date returns have accelerated to +23.38%, while the one-year return stands at a robust +71.74%. The three-year return further extends this positive trajectory to +83.68%. This pattern illustrates a divergence where short-term volatility masks strong medium and long-term growth. The data indicates a clear acceleration in returns as the investment horizon extends from daily fluctuations to multi-year periods.
The fund carries a High volatility label and a beta of 1.10, indicating price movements that are more pronounced than the broader market. A Sharpe ratio of 2.50 suggests that the returns generated have been efficient relative to the amount of risk taken during the measurement period. Despite the high volatility, the maximum drawdown recorded is -32.99%, representing the largest peak-to-trough decline experienced by the fund. This combination of a high beta and a substantial maximum drawdown implies the fund can experience sharp declines during market downturns. Conversely, the high Sharpe ratio indicates that the fund has successfully compensated investors for this elevated risk with significant returns over time.
AI-generated summary based on the data on this page.
XBI Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | State Street Global Advisors | 8.01% | $595M |
| 2 | Apellis Pharmaceuticals Inc | 1.83% | $136M |
| 3 | Alkermes PLC | 1.45% | $108M |
| 4 | Madrigal Pharmaceuticals Inc | 1.38% | $103M |
| 5 | TG Therapeutics Inc | 1.35% | $100M |
| 6 | Insmed Inc | 1.34% | $99M |
| 7 | Scholar Rock Holding Corp | 1.30% | $96M |
| 8 | Apogee Therapeutics Inc | 1.28% | $95M |
| 9 | Protagonist Therapeutics Inc | 1.24% | $93M |
| 10 | Summit Therapeutics Inc | 1.24% | $92M |
Holdings as of 2026-03-31 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 20.4% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how XBI's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With XBI
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with XBI's top 10 — SPDW overlaps most, holding 1 of the same companies as XBI's top 10 (8.0% of XBI's assets).
| ETF | Name | Shared Companies | XBI Weight | Examples |
|---|---|---|---|---|
| SPDW | State Street SPDR Portfolio Developed World ex-US ETF | 1 | 8.0% | State Street Global Advisors |
| SPEM | State Street SPDR Portfolio Emerging Markets ETF | 1 | 8.0% | State Street Global Advisors |
| JNK | State Street SPDR Bloomberg High Yield Bond ETF | 1 | 8.0% | State Street Global Advisors |
| BCI | abrdn Bloomberg All Commodity Strategy K-1 Free ETF | 1 | 8.0% | State Street Global Advisors |
| XSD | State Street SPDR S&P Semiconductor ETF | 1 | 8.0% | State Street Global Advisors |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.65% (as of 2026-07-27) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 18.67 (as of 2026-07-27) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What XBI's Fees Cost You
XBI charges an expense ratio of 0.35% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
XBI Dividend Income Estimator
XBI currently yields 0.36%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
XBI Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is — and average daily volume is 9.1M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $10.7B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: XBI is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
XBI Performance History
| Period | Return |
|---|---|
| 1-Day | -0.54% |
| 1-Week | -3.06% |
| 1-Month | -3.60% |
| 3-Month | +12.69% |
| 6-Month | +17.26% |
| YTD | +23.38% |
| 1-Year | +71.74% |
| 3-Year | +83.68% |
How XBI Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #50 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +26.69% | 0.09% | $20.4B |
| #58 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +24.69% | 0.08% | $40.6B |
| #60 | B |
XBI | State Street SPDR S&P Biotech ETF | +71.74% | 0.35% | $10.7B |
| #86 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +26.80% | 0.084% | $3.22B |
| #107 | B |
IBB | iShares Biotechnology ETF | +40.96% | 0.44% | $9.09B |
| #112 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +60.44% | 0.35% | $428M |
| #146 | B |
PPH | VanEck Pharmaceutical ETF | +29.37% | 0.36% | $879M |
| #167 | B |
IYH | iShares U.S. Healthcare ETF | +24.12% | 0.38% | $3.16B |
| #232 | C |
IHF | iShares U.S. Healthcare Providers ETF | +37.30% | 0.38% | $1.18B |
| #383 | D |
ARKG | ARK Genomic Revolution ETF | +45.46% | 0.75% | $1.73B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -13.86% | 0.38% | $3.02B |